[go: up one dir, main page]

MX2017017097A - Macrociclos diarílicos quirales como moduladores de proteínas quinasas. - Google Patents

Macrociclos diarílicos quirales como moduladores de proteínas quinasas.

Info

Publication number
MX2017017097A
MX2017017097A MX2017017097A MX2017017097A MX2017017097A MX 2017017097 A MX2017017097 A MX 2017017097A MX 2017017097 A MX2017017097 A MX 2017017097A MX 2017017097 A MX2017017097 A MX 2017017097A MX 2017017097 A MX2017017097 A MX 2017017097A
Authority
MX
Mexico
Prior art keywords
modulators
protein kinases
chiral diaryl
macrocycles
diaryl macrocycles
Prior art date
Application number
MX2017017097A
Other languages
English (en)
Inventor
Deng Wei
Ung Jane
Li Yishan
W Rogers Evan
Zhai Dayong
J Cui Jingrong
Original Assignee
Tp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Therapeutics Inc filed Critical Tp Therapeutics Inc
Publication of MX2017017097A publication Critical patent/MX2017017097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a ciertos derivados macrocíclicos diarílicos quirales, composiciones farmacéuticas que los contienes, y métodos para utilizarlos para el tratamiento del cáncer, dolor, trastornos neurológicos, enfermedades autoinmunes e inflamación.
MX2017017097A 2015-07-02 2016-06-30 Macrociclos diarílicos quirales como moduladores de proteínas quinasas. MX2017017097A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188043P 2015-07-02 2015-07-02
US201662353728P 2016-06-23 2016-06-23
PCT/US2016/040329 WO2017004342A1 (en) 2015-07-02 2016-06-30 Chiral diaryl macrocycles as modulators of protein kinases

Publications (1)

Publication Number Publication Date
MX2017017097A true MX2017017097A (es) 2018-05-23

Family

ID=57609146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017017097A MX2017017097A (es) 2015-07-02 2016-06-30 Macrociclos diarílicos quirales como moduladores de proteínas quinasas.

Country Status (13)

Country Link
US (2) US10316044B2 (es)
EP (1) EP3317285B1 (es)
JP (1) JP6871903B2 (es)
KR (1) KR102599788B1 (es)
CN (1) CN107735399B (es)
AU (2) AU2016287568B2 (es)
CA (1) CA2989327A1 (es)
ES (1) ES2864839T3 (es)
IL (1) IL256377A (es)
MX (1) MX2017017097A (es)
RU (1) RU2732405C2 (es)
TW (1) TW201716415A (es)
WO (1) WO2017004342A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
PT3372605T (pt) 2008-10-22 2021-12-09 Array Biopharma Inc Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SMT201900203T1 (it) 2010-05-20 2019-05-10 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
CA2967951C (en) 2014-11-16 2023-11-07 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
EP3317285B1 (en) 2015-07-02 2021-01-27 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RS65593B1 (sr) 2015-07-06 2024-06-28 Turning Point Therapeutics Inc Polimorf diaril makrocikla
PL3733187T3 (pl) * 2015-07-21 2025-01-07 Turning Point Therapeutics, Inc. Chiralny makrocykl diarylowy i jego zastosowanie w leczeniu raka
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
PH12018502124B1 (en) 2016-04-04 2024-04-12 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
PT3458456T (pt) 2016-05-18 2020-12-07 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
WO2018009417A1 (en) * 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CA3031100A1 (en) * 2016-07-28 2018-02-01 Tp Therapeutics, Inc. Macrocycle kinase inhibitors
WO2018064119A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JOP20190213A1 (ar) * 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技（苏州）有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
PL3658148T3 (pl) 2017-07-28 2024-10-07 Turning Point Therapeutics, Inc. Związki makrocykliczne i ich zastosowania
AU2018320021C1 (en) * 2017-08-23 2023-02-23 Centaurus Biopharma Co., Ltd. Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
WO2019094143A1 (en) * 2017-11-10 2019-05-16 Angex Pharmaceutical, Inc. Macrocyclic compounds as trk kinase inhibitors and uses thereof
AU2018392332B2 (en) 2017-12-19 2023-08-03 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating disease
WO2019120194A1 (zh) 2017-12-22 2019-06-27 深圳市塔吉瑞生物医药有限公司 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
US11345703B2 (en) 2018-01-23 2022-05-31 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound
TW201932472A (zh) * 2018-01-30 2019-08-16 大陸商上海吉倍生物技術有限公司 具有大環分子結構的化合物及其用途
CA3093140A1 (en) 2018-03-28 2019-10-03 Fochon Pharmaceuticals, Ltd. Macrocyclic compounds as trk kinases inhibitors
CN110386945B (zh) * 2018-04-18 2021-09-28 广州白云山医药集团股份有限公司白云山制药总厂 一种大环类激酶抑制剂
WO2019210835A1 (zh) * 2018-05-04 2019-11-07 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
WO2019233461A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 原肌球蛋白受体激酶抑制剂及其制备方法和应用
CN110577532B (zh) * 2018-06-08 2022-06-03 江苏威凯尔医药科技有限公司 原肌球蛋白受体激酶抑制剂及其制备方法和应用
CN110950889B (zh) * 2018-09-27 2022-04-05 北京赛林泰医药技术有限公司 一种多靶点激酶抑制剂及其制备方法和用途
US20210403485A1 (en) * 2018-09-29 2021-12-30 Shandong Luye Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivative as selective trk inhibitor
EP4480953B1 (en) 2018-10-22 2026-02-04 Alumis Inc. Tyk2 inhibitors and uses thereof
CN111171049B (zh) * 2018-11-09 2021-06-04 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂及其用途
CN111171020A (zh) 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN111171019A (zh) 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
KR102899985B1 (ko) * 2019-03-11 2025-12-15 알루미스 인크. Tyk2 억제제 및 그의 용도
US11780842B2 (en) * 2019-03-26 2023-10-10 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
JP7318009B2 (ja) * 2019-05-21 2023-07-31 浙江海正薬業股▲ふん▼有限公司 マクロライド誘導体、その製造方法および用途
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
EP3986413A4 (en) * 2019-06-19 2023-06-14 Turning Point Therapeutics, Inc. POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
WO2021098703A1 (zh) 2019-11-18 2021-05-27 南京明德新药研发有限公司 作为高选择性ros1抑制剂的化合物及其应用
CN114867622A (zh) * 2019-11-27 2022-08-05 特普医药公司 涉及二芳基巨环化合物的组合疗法
WO2021108682A1 (en) * 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
EP4069700B1 (en) 2019-12-03 2024-07-03 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
JP2023504866A (ja) * 2019-12-13 2023-02-07 ▲賽▼▲諾▼哈勃▲薬▼▲業▼（成都）有限公司 大環構造を有するフッ素含有複素環誘導体およびその用途
CN113045575B (zh) * 2019-12-27 2022-06-17 成都倍特药业股份有限公司 一种化合物的制备方法及其中间体和中间体的制备方法
CN113527298B (zh) * 2020-04-17 2025-01-03 浙江海正药业股份有限公司 大环内酰胺类衍生物、及其制备方法和用途
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用
JP2023528907A (ja) * 2020-06-04 2023-07-06 シンノハブ ファーマシューティカル カンパニー，リミティド 大環状構造を有する化合物及びその使用
CN114073704B (zh) * 2020-08-14 2023-08-11 赛诺哈勃药业（成都）有限公司 具有大环结构的含氟并杂环衍生物的应用
JP2023541203A (ja) * 2020-09-16 2023-09-28 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
CN114591351B (zh) * 2020-12-03 2023-12-05 成都科岭源医药技术有限公司 一种多环化合物及其制备方法和用途
CN114763360A (zh) * 2021-01-15 2022-07-19 广州百霆医药科技有限公司 手性大环化合物作为蛋白激酶抑制剂及其用途
WO2022218276A1 (zh) * 2021-04-12 2022-10-20 成都倍特药业股份有限公司 含氟大环结构化合物的固体形态、制备方法和应用
WO2023025141A1 (zh) * 2021-08-23 2023-03-02 正大天晴药业集团股份有限公司 含有氨基的大环化合物在治疗trk激酶介导的肿瘤中的用途
CN113582994B (zh) * 2021-09-28 2022-02-11 北京鑫开元医药科技有限公司 具有trk激酶抑制活性的化合物、制备方法、组合物及其用途
CN116063326B (zh) * 2021-11-02 2025-08-05 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
KR20250056969A (ko) 2022-09-07 2025-04-28 수저우 랑루이 바이오파마슈티컬 씨오 엘티디 마크로시클릭 이미다조[1,2-b]피리다진 유도체 및 이의 제조 방법과 용도
CN115746023B (zh) * 2022-10-27 2024-08-09 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
ES2021105B3 (es) 1987-03-07 1991-10-16 Bayer Ag Procedimiento para la obtencion de 5-amino-4,6-dihalogeno piridinas.
AU679053B2 (en) 1993-03-25 1997-06-19 Pharmacia & Upjohn Company Indoletetralins having dopaminergic activity
UA44690C2 (uk) 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
EP1325008B1 (en) 2000-07-31 2005-10-05 F. Hoffmann-La Roche Ag Piperazine derivatives
CA2431187A1 (en) 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
EP1379493A2 (en) 2001-03-23 2004-01-14 Eli Lilly and Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
EA201100450A1 (ru) 2008-09-08 2011-10-31 Мерк Патент Гмбх Макроциклические пирамидины в качестве ингибиторов протеинкиназы
CA2952692C (en) * 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
PT3372605T (pt) * 2008-10-22 2021-12-09 Array Biopharma Inc Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
EP2962566A1 (en) 2008-10-31 2016-01-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR20120087916A (ko) * 2009-10-13 2012-08-07 엘랑코 애니멀 헬쓰 아일랜드 리미티드 마크로시클릭 인테그라제 억제제
WO2011071716A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
US9073926B2 (en) 2009-12-07 2015-07-07 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
SMT201900203T1 (it) * 2010-05-20 2019-05-10 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
UY33597A (es) * 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
US9242917B2 (en) 2011-08-19 2016-01-26 Merck Sharp & Dohme Limited Crystal forms of a HCV protease inhibitor
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
MX347765B (es) 2011-09-30 2017-05-12 Oncodesign Sa Inhibidores macrociclicos de la quinasa flt3.
ES2627347T3 (es) 2011-10-20 2017-07-27 Glaxosmithkline Llc Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
MX381849B (es) 2012-03-09 2025-03-13 Lexicon Pharmaceuticals Inc Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
NZ630719A (en) 2012-03-09 2017-01-27 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CA2899399A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2014173928A1 (en) 2013-04-23 2014-10-30 Lek Pharmaceuticals D.D. Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof
US20160159808A1 (en) 2013-07-24 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
PL3097107T3 (pl) * 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
ES2983908T3 (es) 2014-12-15 2024-10-28 Cmg Pharmaceutical Co Ltd Compuestos heteroarílicos de anillo condensado y su uso como inhibidores de TRK
WO2016133838A1 (en) 2015-02-20 2016-08-25 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
WO2016144846A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
EA201792421A1 (ru) 2015-05-05 2018-05-31 Байер Фарма Акциенгезельшафт Амидозамещенные производные циклогексана
EP3317285B1 (en) 2015-07-02 2021-01-27 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RS65593B1 (sr) 2015-07-06 2024-06-28 Turning Point Therapeutics Inc Polimorf diaril makrocikla
PL3733187T3 (pl) 2015-07-21 2025-01-07 Turning Point Therapeutics, Inc. Chiralny makrocykl diarylowy i jego zastosowanie w leczeniu raka
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
EP4292662A3 (en) 2016-03-04 2024-02-21 Vanderbilt University Substituted indole mcl-1 inhibitors
CA3031100A1 (en) 2016-07-28 2018-02-01 Tp Therapeutics, Inc. Macrocycle kinase inhibitors
JP2020533269A (ja) 2016-12-14 2020-11-19 デベロップメント センター フォー バイオテクノロジー 抗体−薬物複合体およびその使用
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
PL3658148T3 (pl) 2017-07-28 2024-10-07 Turning Point Therapeutics, Inc. Związki makrocykliczne i ich zastosowania

Also Published As

Publication number Publication date
RU2018103907A (ru) 2019-08-05
KR20180023970A (ko) 2018-03-07
EP3317285A1 (en) 2018-05-09
EP3317285A4 (en) 2019-02-27
US10316044B2 (en) 2019-06-11
IL256377A (en) 2018-02-28
EP3317285B1 (en) 2021-01-27
CN107735399A (zh) 2018-02-23
AU2016287568B2 (en) 2020-08-20
WO2017004342A1 (en) 2017-01-05
ES2864839T3 (es) 2021-10-14
US20190284209A1 (en) 2019-09-19
RU2018103907A3 (es) 2019-10-07
KR102599788B1 (ko) 2023-11-07
AU2016287568A1 (en) 2018-01-04
TW201716415A (zh) 2017-05-16
US20180186813A1 (en) 2018-07-05
JP2018519343A (ja) 2018-07-19
CA2989327A1 (en) 2017-01-05
CN107735399B (zh) 2021-01-26
AU2020217336A1 (en) 2020-08-27
US11008337B2 (en) 2021-05-18
RU2732405C2 (ru) 2020-09-16
JP6871903B2 (ja) 2021-05-19

Similar Documents

Publication Publication Date Title
ZA202004100B (en) Diaryl macrocycles as modulators of protein kinases
MX2017017097A (es) Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
PH12019502318A1 (en) Trycyclic heterocycles as bet protein inhibitors
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2019001125A (es) Inhibidores de cinasa macrociclica.
SG10201907582WA (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
SG194718A1 (en) Novel compounds as modulators of protein kinases
MX2015014683A (es) Heterociclos bicíclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
MY188139A (en) Sodium channel modulators for the treatment of pain
GEAP202114756A (en) Combination therapy for the treatment of cancer
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
AU2018380132A8 (en) Tubulin inhibitors
PH12016502307A1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX395492B (es) Usos terapeuticos de l-4 cloroquinurenina.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
TW201612183A (en) Diaryl macrocycles as modulators of protein kinases
MX2018004776A (es) Compuestos oxaazaespiricos con actividad contral el dolor.